RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Heavy fentanyl users may derive greater benefit from a higher dose of extended-release buprenorphine maintenance therapy, a randomized controlled trial suggests.
MedPage Today on MSN
Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder
Extended-release buprenorphine is approved as a once-monthly subcutaneous injection for the treatment of moderate-to-severe ...
About The Study: In this multicenter randomized clinical trial, rapid induction had higher retention than standard induction overall and in patients who tested positive for fentanyl through ...
RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback